Yahoo · Sep 15, 2026
3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026
These stocks have been struggling lately, but they could be underrated buys in the long run.
NV
NYSE · NVO
Novo Nordisk A/S
Healthcare · Drug Manufacturers - General
$42.53
Down-$0.92 (-2.12%)
Updated Sep 16, 2026, 11:00 AM
SID Score
6.3/10
Composite research score
Smart Money
57/100
Neutral
- Market cap
- 223.45B
- P/E ratio
- 12.76
- Dividend yield
- 3.96%
- 52-week range
- $35.12 – $64.16
- Volume
- 8.86M
- Avg. volume
- 16.69M
Price performance
NVO price history
1M range · 20 trading sessions · Daily adjusted prices
NVO closed at $42.53 after 20 trading sessions, down 6.96% for the selected period.
- Last close
- $42.53
- Period change
- -6.96%
- Period low
- $42.53
- Period high
- $48.66
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $42.725 | $43.00 | $42.40 | $42.53 | 8.86M |
| Sep 14, 2026 | $43.66 | $43.71 | $43.0701 | $43.45 | 6.56M |
| Sep 11, 2026 | $43.195 | $43.4951 | $42.7216 | $43.07 | 11.03M |
| Sep 10, 2026 | $44.60 | $44.82 | $44.01 | $44.01 | 6.58M |
| Sep 9, 2026 | $45.00 | $45.395 | $44.52 | $44.56 | 8.83M |
| Sep 8, 2026 | $45.58 | $45.91 | $45.145 | $45.16 | 10.35M |
| Sep 4, 2026 | $46.35 | $46.74 | $46.0417 | $46.60 | 6.22M |
| Sep 3, 2026 | $47.99 | $48.00 | $46.565 | $47.51 | 8.77M |
| Sep 2, 2026 | $46.05 | $47.005 | $45.91 | $46.77 | 13.6M |
| Sep 1, 2026 | $45.80 | $46.16 | $45.065 | $45.12 | 9.36M |
| Aug 31, 2026 | $45.28 | $45.61 | $44.95 | $45.33 | 7.61M |
| Aug 28, 2026 | $46.17 | $46.21 | $45.405 | $45.61 | 8.5M |
| Aug 27, 2026 | $45.97 | $46.33 | $45.70 | $46.26 | 13.02M |
| Aug 26, 2026 | $47.80 | $48.04 | $46.87 | $47.19 | 8.88M |
| Aug 25, 2026 | $47.84 | $48.66 | $47.56 | $48.66 | 15.53M |
| Aug 24, 2026 | $47.09 | $47.30 | $46.565 | $46.92 | 9.67M |
| Aug 21, 2026 | $46.35 | $47.165 | $46.34 | $46.74 | 10.91M |
| Aug 20, 2026 | $46.89 | $46.90 | $46.11 | $46.14 | 9.67M |
| Aug 19, 2026 | $46.01 | $47.195 | $45.841 | $46.48 | 19.51M |
| Aug 18, 2026 | $44.91 | $46.065 | $44.76 | $45.71 | 12.09M |
Latest NVO news
The latest Smart Investors Daily articles mentioning NVO.
Stock researchCompany · Overview
NVO research
Overview
Company profile and research snapshot.
Company profile
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $47.50
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Jul 13, 2026 | BERENBERG | Buy | — |
| Jul 13, 2026 | JYSKE BANK | Hold | — |
| Jul 12, 2026 | GUGGENHEIM SECURITIES LLC | Neutral | — |
| Jul 5, 2026 | EQUISIGHTS | Buy | — |
News briefing
Generated Sep 15, 2026, 9:23 PM
Why Is NVO Down Today? Rebrand and Strategic Shift Weigh on Stock
Novo Nordisk shares fell 2.12% as the company announced a major corporate rebrand to simply 'Novo,' signaling a strategic pivot toward consumer-focused GLP-1 obesity treatments. While the rebrand reflects ambitions in the high-growth metabolic health market, market reaction suggests investor concerns about the company's pharmaceutical identity and competitive positioning.
Bottom line: Novo Nordisk's rebrand and strategic consumer-focused pivot represent a calculated bet on the obesity market's secular growth, yet market reaction suggests investors are concerned about execution risk and competitive intensity. Investors should monitor whether the rebrand resonates with healthcare providers and consumers, track Wegovy's international penetration (especially in China), and watch for competitive pricing pressures as rivals like Ascendis scale their offerings. The company's strong fundamentals and cash generation provide downside support, but near-term volatility may persist as the market assesses the rebrand's strategic wisdom.
Yahoo · Sep 15, 2026
Sector Update: Healthcare Stocks Fall Pre-Bell Tuesday
Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPD
Yahoo · Sep 15, 2026
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.
Yahoo · Sep 15, 2026
Ascendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share Buyback
Ascendis Pharma (ASND) will regain exclusive rights to certain drug treatments for metabolic and car
AI research layers
Interpretive context generated from the platform’s current data sources.
Novo Nordisk A/S Stock Performance
Novo Nordisk A/S shares have experienced notable downward pressure across multiple timeframes, trading at $42.53 per SID market data. The stock has declined 19.98% over the trailing twelve months and dropped 7.0% in the past month alone, while the three-month return shows a more modest decline of 0.98%. NVO currently trades below both key moving averages, sitting 10.31% under its 50-day moving average of $47.42 and 8.07% below its 200-day moving average of $46.26, according to Massive/Polygon technical data. The 14-day relative strength index registers at 36.1, approaching oversold territory below the conventional 30 threshold. Despite the selling pressure, NVO maintains a low beta of 0.352, indicating significantly less volatility than the broader market. Average daily trading volume stands at approximately 16.69 million shares, reflecting sustained institutional participation. The company's market capitalization currently sits at approximately $223.45 billion.
Novo Nordisk A/S Valuation Analysis
Novo Nordisk trades at a price-to-earnings ratio of 12.76, per SID market data, which positions the healthcare giant at a discount relative to many large-cap pharmaceutical peers. However, the PEG ratio of 2.05 suggests that the current valuation may not fully reflect a bargain when adjusted for expected earnings growth, as values above 1.0 generally indicate a premium to growth. The price-to-book ratio stands at 8.43, according to SEC filings, reflecting significant intangible asset value and brand premium characteristic of dominant pharmaceutical franchises. NVO offers a dividend yield of 3.66%, providing meaningful income for shareholders during a period of share price weakness. Within the healthcare sector, Novo Nordisk's valuation profile reflects the market's recalibration of GLP-1 class growth expectations. The combination of a sub-13 P/E and above-average dividend yield represents a notable shift from the stock's historically elevated multiples over the prior two years.
Smart Money Activity for NVO
Novo Nordisk's composite smart money score stands at 57 out of 100, generating a neutral signal per SID market data. Institutional activity represents the strongest component, scoring 23.0 out of 25, indicating robust positioning by major fund managers according to 13F institutional filings. This high institutional score aligns with NVO's large-cap status and inclusion in major global indices. Insider activity scores 12.5 out of 25, reflecting a moderate level of transactions by company executives and directors per SEC Form 4 filings, with no outsized buying or selling signals. Dark pool activity registers at 9.5 out of 25, suggesting relatively muted off-exchange block trading interest at current price levels. Congressional trading activity scores 12 out of 25, indicating average legislative interest in the name. The divergence between strong institutional conviction and weaker dark pool activity may reflect a holding pattern among large allocators who maintain existing positions without aggressively adding at current valuations. Overall, the data presents a mixed but institutionally supported picture.
Novo Nordisk A/S Earnings Outlook
Novo Nordisk's upcoming earnings cycle features four reporting dates clustered in August 2026, with consensus analyst estimates holding steady at $0.81 per share for each quarter, according to analyst estimates compiled by SID. The consistency across all four quarterly estimates suggests analysts are projecting stable sequential earnings performance throughout the fiscal year. At the current share price of $42.53, these estimates imply annualized earnings of approximately $3.24 per share, aligning with the trailing P/E ratio of 12.76 per company earnings reports. The first report is scheduled for August 28, 2026, with subsequent releases on August 25, August 21, and August 18. No actual earnings data or surprise figures are yet available for these forward periods. Investors will be monitoring revenue contributions from Wegovy and Ozempic, as well as pipeline updates, for catalysts that could drive estimate revisions above or below the current $0.81 consensus.
Wall Street Analyst Ratings for NVO
Recent Wall Street coverage of Novo Nordisk reflects a predominantly constructive but nuanced outlook, per SID consensus data. On July 13, 2026, both Rothschild & Co Redburn and Berenberg maintained their Buy ratings on the stock, signaling continued confidence in the company's fundamental trajectory. Equisights also reiterated a Buy rating on July 5, according to Wall Street analyst reports. However, Jyske Bank downgraded NVO from Buy to Hold on July 13, representing the sole negative revision in the recent coverage window and introducing a dissenting view amid the broader bullish consensus. Guggenheim Securities maintained its Neutral rating on July 12, reflecting a wait-and-see approach. Across the five most recent analyst actions, three firms hold Buy ratings, one rates Hold, and one rates Neutral. The downgrade from Jyske Bank is notable given NVO's 19.98% decline over the past year, suggesting some analysts view the current risk-reward profile as less compelling than during prior coverage periods.
